#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14958	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2162	688.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1709	1709	T	821	T,C	764,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14958	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2162	688.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1443	1443	C	861	C	792	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14958	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2162	688.6	0	HET	.	.	.	A109G	.	109	109	A	368	368	A	854	A,G	570,217	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27564	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3566	769.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1626	1626	A	961	A,G	897,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27564	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3566	769.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2260	2260	C	898	C	825	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27564	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3566	769.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2334	2334	A	857	A	808	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27564	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3566	769.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	2886	2886	C	844	C	787	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27564	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3566	769.4	0	HET	.	.	.	C2626CGGGGG,CGGGG	.	2626	2626	C	2915	2915	C	841	CGGGGG,CGGGG	578,177	.	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	27	1992	folP	855	855	100.0	folP.l15.c4.ctg.1	1590	124.7	1	SNP	p	R229S	0	.	.	685	687	CGC	1120	1122	CGC	241;237;238	C,A;G;C	224,1;222;221	folP.WHO_L_00516:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5600	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3294	169.3	1	SNP	p	S91F	0	.	.	271	273	TCC	556	558	TCC	166;163;162	T;C;C	152;150;149	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5600	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3294	169.3	1	SNP	p	D95G	0	.	.	283	285	GAC	568	570	GAC	156;158;158	G;A;C	143;144;142	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5600	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3294	169.3	1	SNP	p	D95N	0	.	.	283	285	GAC	568	570	GAC	156;158;158	G;A;C	143;144;142	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1738	mtrR	633	633	99.68	mtrR.l15.c4.ctg.1	1339	128.9	0	.	p	.	0	S32W	NONSYN	94	96	TCG	434	436	TGG	217;220;220	T;G;G	196;204;195	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1738	mtrR	633	633	99.68	mtrR.l15.c4.ctg.1	1339	128.9	0	.	p	.	0	D79N	NONSYN	235	237	GAT	575	577	AAT	211;211;211	A,G;A;T	193,1;192;193	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1738	mtrR	633	633	99.68	mtrR.l15.c4.ctg.1	1339	128.9	1	SNP	p	G45D	0	.	.	133	135	GGC	473	475	GGC	226;229;227	G;G;C	208;210;209	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1002	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1137	87.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4994	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2947	168.7	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1504	1506	ATC	221;220;219	A,G;T;C	201,1;202;203	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4994	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2947	168.7	0	.	p	.	0	V421A	NONSYN	1261	1263	GTC	1615	1617	GCC	206;205;205	G;C,T;C	196;193,2;195	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4994	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2947	168.7	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1657	1659	GCA	199;199;201	G;C;A	181;177;179	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4994	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2947	168.7	1	SNP	p	D86N	0	.	.	256	258	GAC	610	612	GAC	193;193;194	G;A;C	177;179;179	parC.WHO_G_00206c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4994	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2947	168.7	1	SNP	p	S87I	0	.	.	259	261	AGT	613	615	AGT	201;204;204	A;G;T	187;188;187	parC.WHO_G_00206c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4994	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2947	168.7	1	SNP	p	S87R	0	.	.	259	261	AGT	613	615	AGT	201;204;204	A;G;T	187;188;187	parC.WHO_G_00206c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4994	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2947	168.7	1	SNP	p	S87W	0	.	.	259	261	AGT	613	615	AGT	201;204;204	A;G;T	187;188;187	parC.WHO_G_00206c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	4994	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2947	168.7	1	SNP	p	S88P	0	.	.	262	264	TCC	616	618	TCC	204;202;200	T;C;C	186;186;186	parC.WHO_G_00206c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4402	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2638	166.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1509	1511	GGC	180;179;174	G;G;C	166;166;159	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4414	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2380	184.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1261	1263	GCA	241;241;241	G;C;A	221;222;226	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4414	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2380	184.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1264	1266	ATC	241;243;243	A;T;C	225;226;230	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4414	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2380	184.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1276	1278	GTG	247;245;244	G;T;G	232;228;229	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4414	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2380	184.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1276	1278	GTG	247;245;244	G;T;G	232;228;229	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4414	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2380	184.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1780	1782	ACC	234;236;236	A;C;C	220;223;222	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4414	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2380	184.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1834	1836	GCG	227;223;224	G;C;G	199;179;190	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4414	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2380	184.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1834	1836	GCG	227;223;224	G;C;G	199;179;190	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4414	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2380	184.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1957	1959	GGC	202;198;198	G,A;G;C	186,1;182;185	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4414	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2380	184.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1966	1968	GGC	190;189;189	G;G;C,G	173;174;172,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4414	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2380	184.5	1	SNP	p	L552S	0	.	.	1654	1656	CTG	1984	1986	CTG	179;177;179	C,G;T,C;G	142,7;123,1;133	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6012	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3121	192.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2198	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1979	110.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	589	589	C	152	C	139	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	27	2900	porB1a	984	984	100.0	porB1a.l15.c4.ctg.1	1684	171.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	11306	rpoB	4179	4179	100.0	rpoB.l15.c30.ctg.1	4958	227.4	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2036	2038	CAT	272;275;273	C;A;T	249;251;247	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1206	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1038	115.4	1	SNP	p	V57M	1	.	.	169	171	ATG	503	505	ATG	245;242;244	A;T,C;G	232;229,1;233	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
